File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Proteomics of hepatocellular carcinoma: Serum vimentin as a surrogate marker for small tumors (≤2 cm)

TitleProteomics of hepatocellular carcinoma: Serum vimentin as a surrogate marker for small tumors (≤2 cm)
Authors
KeywordsAFP
Biomarker
Cancer screening
HCC
Tumor detection
Tumor size
Issue Date2010
PublisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/journals/jprobs
Citation
Journal Of Proteome Research, 2010, v. 9 n. 4, p. 1923-1930 How to Cite?
AbstractSmall hepatocellular carcinomas (HCCs) can be effectively cured by surgery with good clinical outcomes. However, the conventional AFP marker is ineffective in detecting small tumors. Here we employed a proteomic profiling approach to identify a candidate marker for HCC (≤2 cm) in tumor tissues and then evaluate its clinical feasibility in patients? sera. The study was divided into 2 phases. (i) Biomarker discovery: we collected 76 frozen liver tissues (40 HCC and 36 controls) for proteomics profiling. Candidate protein markers were identified by MALDI-TOF/TOF and confirmed by immunoblot and qPCR. (ii) Clinical evaluation: Selected biomarker was tested by ELISA for sensitivity and specificity using serum samples from a separate cohort of 152 subjects (88 HCC and 64 controls). Vimentin was found significantly overexpressed in HCC, in particular the small-size subgroup (≤2 cm) with p < 0.01. When tested in the serum samples, vimentin level was significantly higher in small tumors than the non-neoplastic controls (AUC = 0.69 and p < 0.01). Further analysis suggested that elevated circulating vimentin level could detect small HCC at 40.91% sensitivity and 87.50% specificity. Moreover, vimentin was found to be superior to serum AFP assayed at different cut-offs in detecting small tumors. When combined with AFP, the detection sensitivity and specificity could be further enhanced to 58.77 and 98.15%, respectively. In conclusion, serum vimentin is a potential surrogate marker, either alone or in combination with AFP, for detection of small HCCs. © 2010 American Chemical Society.
Persistent Identifierhttp://hdl.handle.net/10722/88478
ISSN
2014 Impact Factor: 4.245
2014 SCImago Journal Rankings: 1.606
ISI Accession Number ID
Funding AgencyGrant Number
Research Grants Council of Hong Kong771607M
National Medical Research Council
Funding Information:

The work was supported by grants from the Research Grants Council of Hong Kong (771607M) and National Medical Research Council to J.M.L. We also thank for the generous donation from the Sun Chien Yeh Research Foundation for Hepatobiliary and Pancreatic Surgery. We sincerely acknowledge Dr. W. C. Yu for giving clinical assistance in specimen collection and preparation. We also thank Dr. Wilson Y.P. Ching in Department of Anatomy, The University of Hong Kong for providing the monoclonal vimentin antibody in our preliminary studies. Irene Ng is Loke Yew Professor of Pathology.

References

 

DC FieldValueLanguage
dc.contributor.authorSun, Sen_HK
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorLee, NPen_HK
dc.contributor.authorYeung, Cen_HK
dc.contributor.authorChan, KLen_HK
dc.contributor.authorNg, IOLen_HK
dc.contributor.authorDay, PJRen_HK
dc.contributor.authorLuk, JMen_HK
dc.date.accessioned2010-09-06T09:43:54Z-
dc.date.available2010-09-06T09:43:54Z-
dc.date.issued2010en_HK
dc.identifier.citationJournal Of Proteome Research, 2010, v. 9 n. 4, p. 1923-1930en_HK
dc.identifier.issn1535-3893en_HK
dc.identifier.urihttp://hdl.handle.net/10722/88478-
dc.description.abstractSmall hepatocellular carcinomas (HCCs) can be effectively cured by surgery with good clinical outcomes. However, the conventional AFP marker is ineffective in detecting small tumors. Here we employed a proteomic profiling approach to identify a candidate marker for HCC (≤2 cm) in tumor tissues and then evaluate its clinical feasibility in patients? sera. The study was divided into 2 phases. (i) Biomarker discovery: we collected 76 frozen liver tissues (40 HCC and 36 controls) for proteomics profiling. Candidate protein markers were identified by MALDI-TOF/TOF and confirmed by immunoblot and qPCR. (ii) Clinical evaluation: Selected biomarker was tested by ELISA for sensitivity and specificity using serum samples from a separate cohort of 152 subjects (88 HCC and 64 controls). Vimentin was found significantly overexpressed in HCC, in particular the small-size subgroup (≤2 cm) with p < 0.01. When tested in the serum samples, vimentin level was significantly higher in small tumors than the non-neoplastic controls (AUC = 0.69 and p < 0.01). Further analysis suggested that elevated circulating vimentin level could detect small HCC at 40.91% sensitivity and 87.50% specificity. Moreover, vimentin was found to be superior to serum AFP assayed at different cut-offs in detecting small tumors. When combined with AFP, the detection sensitivity and specificity could be further enhanced to 58.77 and 98.15%, respectively. In conclusion, serum vimentin is a potential surrogate marker, either alone or in combination with AFP, for detection of small HCCs. © 2010 American Chemical Society.en_HK
dc.languageengen_HK
dc.publisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/journals/jprobsen_HK
dc.relation.ispartofJournal of Proteome Researchen_HK
dc.subjectAFPen_HK
dc.subjectBiomarkeren_HK
dc.subjectCancer screeningen_HK
dc.subjectHCCen_HK
dc.subjectTumor detectionen_HK
dc.subjectTumor sizeen_HK
dc.subject.meshCarcinoma, Hepatocellular - blood - diagnosis - pathology-
dc.subject.meshLiver Neoplasms - blood - diagnosis - pathology-
dc.subject.meshProteomics - methods-
dc.subject.meshTumor Markers, Biological - blood-
dc.subject.meshVimentin - blood-
dc.titleProteomics of hepatocellular carcinoma: Serum vimentin as a surrogate marker for small tumors (≤2 cm)en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1535-3893&volume=9&issue=4&spage=1923&epage=1930&date=2010&atitle=Proteomics+of+hepatocellular+carcinoma:+serum+vimentin+as+a+surrogate+marker+for+small+tumors+(≤2+cm)en_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.emailLee, NP: nikkilee@hku.hken_HK
dc.identifier.emailNg, IOL: iolng@hkucc.hku.hken_HK
dc.identifier.emailLuk, JM: jmluk@hkucc.hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.identifier.authorityLee, NP=rp00263en_HK
dc.identifier.authorityNg, IOL=rp00335en_HK
dc.identifier.authorityLuk, JM=rp00349en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1021/pr901085zen_HK
dc.identifier.pmid20121168en_HK
dc.identifier.scopuseid_2-s2.0-77950647292en_HK
dc.identifier.hkuros169635en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77950647292&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume9en_HK
dc.identifier.issue4en_HK
dc.identifier.spage1923en_HK
dc.identifier.epage1930en_HK
dc.identifier.isiWOS:000276215700028-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridSun, S=21740136100en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK
dc.identifier.scopusauthoridLee, NP=7402722690en_HK
dc.identifier.scopusauthoridYeung, C=26531966700en_HK
dc.identifier.scopusauthoridChan, KL=37004089600en_HK
dc.identifier.scopusauthoridNg, IOL=7102753722en_HK
dc.identifier.scopusauthoridDay, PJR=7202148832en_HK
dc.identifier.scopusauthoridLuk, JM=7006777791en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats